The British biotechnology company Engitix Therapeutics Ltd has announced the appointment of Mike Burbridge as vice president, oncology and immuno-oncology. Dr Burbridge joins the company from the Servier Centre for Therapeutic Innovation in Oncology in France where he was programme director, external innovation. His previous roles at Servier included director, translational and clinical research, oncology.
Dr Burbridge received his PhD in pharmacology from the University of Liverpool, UK. Engitix was founded in 2016 to commercialise research carried out by the Institute for Liver and Digestive Health at University College London, UK.
Engitix announced the appointment on 4 May 2021.
Copyright 2021 Evernow Publishing Ltd.